Newton purchased back Esperion in May 2008 with funding from Aisling Capital, Alta Partners, Domain Associates and Ann Arbor-based Arboretum Ventures. The company went public again in 2013, trading on the NASDAQ as ESPR.
In the news
Biotech firm Esperion Therapeutics has entered the second phase of the government's required three-stage regulatory process to test the effectiveness of its top drug candidate, the company announced today. The firm, led by Ann Arbor entrepreneur Roger Newton, the scientist who co-discovered "bad" cholesterol-lowering drug Lipitor, said it had started its Phase 2 clinical study for a drug currently known as ETC-1002. The drug aims to help the body fight triglycerides and LDL cholesterol.